seekingalpha.com / .seekingalpha-com / Page 10

The Voya Intermediate Bond Fund outperformed its benchmark Index on a NAV basis for Q3 2024. Click here to read the full commentary.

Target reported its Q3 FY24 results where its revenue grew 1.0% YoY to $25.68B. Click here to find out why I downgrade TGT stock to a hold.

Learn how earnings, market sentiment, and chart structures affect stock movements like ADBE, with a focus on risk management and capital preservation. Read more here.

In Q3 2024, the Lazard Real Assets Portfolio inst. and open shares both appreciated 10.7%, outperforming their benchmark index. Click here to read the full commentary.

In Q3 2024, the Lazard Opportunistic Strategies Portfolio's Institutional Shares and Open Shares both underperformed their benchmark indexes. Click here to read the full commentary.

US large-, small-, mid-cap, and global equities broadly, continued their climb higher in the third quarter of 2024. Click here to read the full commentary.

The Lazard US Short Duration Fixed Income Portfolio advanced 3.11% (Institutional shares, net of fees) in Q3 2024, outperforming its benchmark. Click here to read the full commentary.

Is the S&P 500 overvalued? Click here to learn why comparing stocks to an expensive index may not be the best strategy for investors.

The election results bring a new phase for the economy. While inflation has eased, prices remain high, and tackling them will be a challenge for President Trump. Read more here.

Learn about Ionis Pharmaceuticals' innovative RNA-targeted therapy and their potential for significant revenue growth. Read my IONS thesis.